evidencegaps
Primary study · included by 2 reviews

225 Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177 Lu-PSMA-617 Radioligand Therapy : Pilot Experience From a Prospective Registry.

Rosar 2024 · Rosar Florian, Burgard Caroline, Rohloff Luna Vanessa, et al. · Clinical nuclear medicine · 2024

Included by

Therapeutic outcomes of ²²⁵Ac/¹⁷⁷Lu-PSMA combination therapy in advanced metastatic Castration-Resistant prostate cancer: A systematic review and Meta-Analysis.
Non-Cochrane · intervention · 2026 · cited as Rosar 2024 (augmentation, n=33) · Reference 29; Table 1; Figure 2A
Outcome this study informsPooled effectEvidenceCertainty
PSA decline of 50% or more (PSA50 response)
[225Ac]Ac-/[177Lu]Lu-PSMA combination (tandem) radioligand therapy vs None (single-arm studies)
Proportion (random-effects, REML) 0.47 [0.37, 0.56]8 studies · 323 participantsGRADE not reported
PSA decline of 50% or more (PSA50 response)
[225Ac]Ac-/[177Lu]Lu-PSMA combination (tandem) radioligand therapy vs None (single-arm studies)
Proportion (random-effects, REML) 0.44 [0.32, 0.56]6 studies · 169 participantsGRADE not reported
Beyond [177Lu]Lu-PSMA: a meta-analysis of safety and efficacy of emerging PSMA radioligand therapy agents.
Non-Cochrane · intervention · 2026 · cited as Rosar 2024 · Reference list refs 21-53; Table 2; Supplementary Table 5

The review does not say which of its outcomes this study informs.

2 including reviews in total.